Drug Interactions in Special Populations — MCQs
Which of the following drugs can cause cartilage damage in children?
Which of the following is not considered a pharmacogenetic condition?
What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?
Which of the following drugs is given during pregnancy, resulting in fetal abnormalities such as cleft lip and central nervous system defects?
In which of the following conditions is digoxin most likely to accumulate to toxic levels?
Which of the following DPP-IV inhibitors is safe for use in chronic kidney disease patients without requiring dose modification?
All of the following are risk factors for renal toxicity caused by aminoglycosides EXCEPT:
In SCHWARTZ formula for calculation of creatinine clearance in a child, the constant depends on the following except –
Which of the following antimicrobials should not be given to a chronic asthmatic patient managed on theophylline therapy?
Which antiretroviral drug should be avoided in a known sputum-positive pulmonary tuberculosis patient who is currently on INH, rifampicin, pyrazinamide, and ethambutol, and has a CD4 count of 100 cells/dL and a viral load of more than 50,000 copies/mL, given that the patient is HIV-positive?
Drug Interactions in Special Populations Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following drugs can cause cartilage damage in children?
- A. Cotrimoxazole and other sulfonamides
- B. Penicillin and other beta-lactams
- C. Metronidazole and other nitroimidazoles
- D. Ciprofloxacin and other fluoroquinolones (Correct Answer)
Explanation: ***Ciprofloxacin and other fluoroquinolones*** - Fluoroquinolones, including ciprofloxacin, are known to cause **arthropathy** (joint disease) and **cartilage damage** in growing children and adolescents [1]. - This adverse effect has limited their use in pediatric populations, typically reserved for severe infections where other effective and safer alternatives are unavailable [1]. *Cotrimoxazole and other sulfonamides* - Sulfonamides are primarily associated with adverse effects like **hypersensitivity reactions** (e.g., Stevens-Johnson syndrome), **bone marrow suppression**, and **crystalluria**. - They are not typically linked to cartilage damage in children. *Penicillin and other beta-lactams* - Penicillins and other beta-lactam antibiotics are generally considered **safe in children** and are a common choice for pediatric infections. - Their primary adverse effects are hypersensitivity reactions, such as **rashes** or **anaphylaxis**, and gastrointestinal disturbances, not cartilage damage. *Metronidazole and other nitroimidazoles* - Metronidazole's main adverse effects include **gastrointestinal upset**, **metallic taste**, and **neurological symptoms** (e.g., peripheral neuropathy, seizures with high doses). - There is no known association between metronidazole and cartilage damage in children.
Question 2: Which of the following is not considered a pharmacogenetic condition?
- A. Adenosine deaminase deficiency (Correct Answer)
- B. Coumarin insensitivity
- C. G6PD deficiency
- D. Malignant hyperthermia
Explanation: ***Adenosine deaminase deficiency*** - **Adenosine deaminase deficiency** (ADA deficiency) is an **autosomal recessive** metabolic disorder causing severe immunodeficiency, primarily affecting gene function rather than drug response. - While it can be treated with enzyme replacement therapies or gene therapy, it is not primarily characterized by an altered response to standard therapeutic drugs. *Coumarin insensitivity* - **Coumarin insensitivity** refers to an individual's reduced response to **warfarin (a coumarin derivative)**, requiring higher doses to achieve effective anticoagulation. - This is a well-documented **pharmacogenetic condition**, often linked to variations in genes like *CYP2C9* and *VKORC1*. *G6PD deficiency* - **Glucose-6-phosphate dehydrogenase (G6PD) deficiency** is an X-linked genetic disorder that can lead to **hemolytic anemia** upon exposure to certain drugs (e.g., antimalarials, sulfonamides, aspirin) and fava beans [1]. - It is a classic example of a **pharmacogenetic condition** where genetic variations dictate drug-induced adverse reactions [1]. *Malignant hyperthermia* - **Malignant hyperthermia** is a life-threatening, inherited disorder triggered by certain **inhalation anesthetics** (e.g., halothane, isoflurane) and the **depolarizing muscle relaxant succinylcholine**. - This condition is caused by mutations in genes involved in calcium regulation in muscle cells (e.g., *RYR1*) and is a critical **pharmacogenetic response**.
Question 3: What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?
- A. First pass kinetics
- B. First order kinetics
- C. Zero order kinetics (Correct Answer)
- D. Second order kinetics
Explanation: ***Zero order kinetics*** - This mechanism occurs when the **metabolic enzymes become saturated at high drug concentrations**, leading to a constant amount (not a constant percentage) of drug being eliminated per unit time. - Alcohol, aspirin, and phenytoin are examples of drugs that exhibit **saturable metabolism**, transitioning from first-order to zero-order kinetics at higher doses. *First pass kinetics* - This describes the **metabolism of a drug by the liver or gut wall enzymes before it reaches systemic circulation** after oral administration. - While relevant to the oral bioavailability of these drugs, it does not describe the specific mechanism of elimination at high doses. *First order kinetics* - In this mechanism, a **constant fraction or percentage of the drug is eliminated per unit of time**, meaning the rate of elimination is directly proportional to the drug concentration. - Most drugs follow first-order kinetics at therapeutic doses because metabolizing enzymes are not saturated. *Second order kinetics* - This is a **less common pharmacokinetic model** where the rate of elimination is proportional to the square of the drug concentration or involves two reactants. - It does not typically describe the common elimination patterns of most drugs, including alcohol, aspirin, and phenytoin.
Question 4: Which of the following drugs is given during pregnancy, resulting in fetal abnormalities such as cleft lip and central nervous system defects?
- A. Warfarin
- B. Phenytoin
- C. Valproic acid
- D. Retinoic acid (Vitamin A derivative) (Correct Answer)
Explanation: ***Retinoic acid (Vitamin A derivative)*** - **Retinoic acid** (including isotretinoin) is a **potent teratogen** with a characteristic pattern of malformations including **craniofacial defects (cleft lip/palate)**, **cardiac abnormalities** (transposition of great arteries, VSD), and **severe CNS defects** (hydrocephalus, microcephaly, neural tube defects) - The mechanism involves **disruption of gene expression** during embryogenesis, particularly affecting **neural crest cell migration** critical for facial and cardiac development - The combination of **cleft lip + CNS defects** is characteristic of retinoic acid embryopathy, making it the most fitting answer *Phenytoin* - **Phenytoin** causes **fetal hydantoin syndrome** with craniofacial anomalies (cleft lip/palate in ~5-10% of cases), **hypoplastic nails and distal phalanges**, wide-set eyes, and mild developmental delays - While cleft lip can occur, the overall pattern emphasizes **digital/nail hypoplasia** and milder CNS effects compared to retinoic acid *Valproic acid* - **Valproic acid** is primarily associated with **neural tube defects** (spina bifida in 1-2% of exposures), the hallmark of valproate embryopathy - Can cause minor facial anomalies and cardiac defects, but the **characteristic feature is spina bifida**, not cleft lip *Warfarin* - **Warfarin** causes **fetal warfarin syndrome** with distinctive features: **nasal hypoplasia**, **stippled epiphyses** (chondrodysplasia punctata), and potential CNS defects from hemorrhage - Does **not** typically cause cleft lip; the skeletal abnormalities are the defining feature
Question 5: In which of the following conditions is digoxin most likely to accumulate to toxic levels?
- A. Renal insufficiency (Correct Answer)
- B. Chronic hepatitis
- C. Advanced cirrhosis
- D. Chronic pancreatitis
Explanation: ***Renal insufficiency*** - **Digoxin** is primarily excreted unchanged by the **kidneys**, so impaired renal function significantly prolongs its half-life and leads to drug accumulation. - Patients with kidney failure require **dose adjustments** or closer monitoring of **digoxin levels** to prevent toxicity. *Chronic hepatitis* - **Chronic hepatitis** primarily affects the **liver's metabolic capacity**, which is not the primary route of **digoxin elimination**. - While severe hepatic dysfunction can subtly impact drug disposition, it's not the main reason for **digoxin accumulation** like **renal insufficiency**. *Advanced cirrhosis* - **Advanced cirrhosis** involves severe liver dysfunction, which can alter drug metabolism and protein binding. - However, **digoxin's elimination** is mainly renal, so liver disease alone does not typically lead to significant accumulation unless accompanied by **renal impairment**. *Chronic pancreatitis* - **Chronic pancreatitis** is a disorder of the pancreas and does not directly impact the **excretion or metabolism** of **digoxin**. - It would not be expected to cause **digoxin accumulation** to toxic levels.
Question 6: Which of the following DPP-IV inhibitors is safe for use in chronic kidney disease patients without requiring dose modification?
- A. Sitagliptin
- B. Vildagliptin
- C. Linagliptin (Correct Answer)
- D. Saxagliptin
Explanation: ***Linagliptin*** - Unlike other **DPP-IV inhibitors**, **linagliptin** is primarily eliminated via **biliary/fecal excretion** (~85%) rather than renal excretion. - This unique elimination pathway makes it **safe** for use in patients with **chronic kidney disease** at its usual dose, without the need for dose adjustment. - It is the **only DPP-IV inhibitor** that does not require dose modification in CKD. *Sitagliptin* - **Sitagliptin** is primarily eliminated by the **kidneys** (~80% renal excretion), requiring **significant dose adjustments** in patients with **renal impairment**. - Without dose modification, there is an increased risk of **drug accumulation** and adverse effects in CKD patients. *Vildagliptin* - **Vildagliptin** undergoes **hydrolysis** with subsequent **renal excretion** of inactive metabolites, requiring **dose reduction** in patients with moderate to severe **renal impairment**. - Not recommended in severe renal impairment (eGFR <50 mL/min). *Saxagliptin* - **Saxagliptin** is partially eliminated via **renal excretion** and requires **dose reduction** by 50% in patients with moderate to severe **CKD**. - Both parent drug and active metabolite accumulate in renal impairment, necessitating dose adjustment.
Question 7: All of the following are risk factors for renal toxicity caused by aminoglycosides EXCEPT:
- A. Hypokalemia
- B. Aminoglycoside administration in recent past
- C. Simultaneous use of penicillin (Correct Answer)
- D. Elderly patient
Explanation: ***Simultaneous use of penicillin*** - Penicillins are **not considered a major risk factor** for aminoglycoside nephrotoxicity. - While aminoglycosides and penicillins can be inactivated when mixed **in vitro** (in IV solutions), this does not translate to a protective effect against renal toxicity **in vivo**. - The major nephrotoxic drug combinations with aminoglycosides include **vancomycin, amphotericin B, cyclosporine, NSAIDs, and loop diuretics** - not penicillins. *Hypokalemia* - **Electrolyte imbalances**, such as hypokalemia, can worsen renal function and increase the susceptibility of the kidneys to damage from nephrotoxic drugs like aminoglycosides. - **Volume depletion** and electrolyte disturbances are common comorbidities that exacerbate aminoglycoside-induced acute kidney injury. *Aminoglycoside administration in recent past* - Prior exposure to aminoglycosides, especially within a short period, can lead to **cumulative toxicity** due to incomplete renal recovery from previous dosing. - The kidneys require time to regenerate epithelial cells damaged by aminoglycosides, and repeated exposure increases the risk of **irreversible damage**. *Elderly patient* - **Age** is a significant risk factor because elderly patients often have **decreased renal blood flow** and a reduced number of functional nephrons. - The **glomerular filtration rate (GFR)** naturally declines with age, making the kidneys more vulnerable to drug-induced injury.
Question 8: In SCHWARTZ formula for calculation of creatinine clearance in a child, the constant depends on the following except –
- A. Age
- B. Mass
- C. Severity of renal failure (Correct Answer)
- D. Method of estimation of creatinine
Explanation: ***Severity of renal failure*** - The constant in the **Schwartz formula** primarily accounts for factors like muscle mass and maturation, not the severity of renal failure itself. - The formula is designed to estimate glomerular filtration rate (GFR) over a range of renal function, with the creatinine value reflecting the severity, not the constant. *Age* - The original Schwartz formula uses an age-dependent constant, with different values for infants, children, and adolescents, reflecting changes in **muscle mass** and **creatinine generation** with age. - Specifically, constants like 0.33, 0.45, 0.55, and 0.65 are used depending on the patient's age group. *Mass* - The constant implicitly accounts for differences in **muscle mass** and body composition, which are related to age and sex, influencing creatinine production. - The formula itself includes **height** in cm as a direct variable, which is a proxy for lean body mass. *Method of estimation of creatinine* - The constant is adjusted based on the method used to measure **serum creatinine**, specifically whether it's an **enzymatic** method or a **Jaffe reaction-based** method. - Different constants are necessary because Jaffe assays can overestimate true creatinine levels due to interference from non-creatinine chromogens.
Question 9: Which of the following antimicrobials should not be given to a chronic asthmatic patient managed on theophylline therapy?
- A. Amoxicillin
- B. Cefotaxime
- C. Erythromycin (Correct Answer)
- D. Cotrimoxazole
Explanation: ***Erythromycin*** - **Erythromycin**, a macrolide antibiotic, is a potent inhibitor of the **cytochrome P450 (CYP450) enzyme system**, specifically **CYP1A2**, which is the primary enzyme responsible for theophylline metabolism. - Co-administration of erythromycin can significantly **increase theophylline levels**, leading to toxicity such as **nausea, vomiting, seizures, or cardiac arrhythmias.** - This interaction is clinically significant and erythromycin should be avoided in patients on theophylline therapy. *Amoxicillin* - **Amoxicillin** is a penicillin-class antibiotic that has minimal interaction with theophylline metabolism. - It does not significantly inhibit the **CYP1A2 enzyme** and is generally considered safe to use with theophylline. *Cefotaxime* - **Cefotaxime**, a third-generation cephalosporin, does not significantly affect the metabolism of theophylline. - It does not inhibit **CYP1A2 enzymes** and is safe for use in patients on theophylline therapy. *Cotrimoxazole* - **Cotrimoxazole** (trimethoprim/sulfamethoxazole) may slightly increase theophylline levels by inhibiting some CYP450 isoenzymes, but its effect is generally less pronounced than that of erythromycin. - While caution and monitoring are advised, it is not as strongly contraindicated as erythromycin due to a lower risk of significant toxicity in most cases.
Question 10: Which antiretroviral drug should be avoided in a known sputum-positive pulmonary tuberculosis patient who is currently on INH, rifampicin, pyrazinamide, and ethambutol, and has a CD4 count of 100 cells/dL and a viral load of more than 50,000 copies/mL, given that the patient is HIV-positive?
- A. Indinavir
- B. Ritonavir (Correct Answer)
- C. Lamivudine
- D. Efavirenz
Explanation: ***Ritonavir (Correct Answer)*** - **Ritonavir** is the most critical drug to avoid due to severe drug-drug interactions with **rifampicin** - **Rifampicin** is a potent CYP3A4 inducer that dramatically reduces ritonavir plasma concentrations by 75-90%, rendering it completely ineffective - Ritonavir is commonly used as a pharmacokinetic booster for other protease inhibitors, making this interaction particularly significant - **Contraindicated** with rifampicin-based TB regimens *Indinavir* - Also a protease inhibitor metabolized via CYP3A4 - Should also be **avoided with rifampicin** as levels are reduced by approximately 90% - However, indinavir is rarely used in modern ART regimens due to high pill burden, need for dietary restrictions, and significant side effects (nephrolithiasis) - Less commonly used than ritonavir, making ritonavir the better answer *Lamivudine* - Nucleoside reverse transcriptase inhibitor (NRTI) with **renal elimination** - Not metabolized by CYP450 enzymes - **No significant interactions** with rifampicin or other anti-TB drugs - Safe and commonly used in TB/HIV co-infection *Efavirenz* - Non-nucleoside reverse transcriptase inhibitor (NNRTI) that **can be safely co-administered** with rifampicin - Standard dose (600 mg daily) is generally adequate, though some guidelines recommend considering 800 mg in patients >60 kg - **Preferred NNRTI** for TB/HIV co-infection according to WHO guidelines - Well-studied and effective combination with rifampicin-based TB therapy
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free